Successful response to rituximab in two cases of acquired haemophilia refractory to standard-therapy

International Journal of Hematology

Volumn 87, Issue 5, 2008, Pages 545-549

  Machado, P ^a   Raya, J M ^a,b   Martin T ^a   Morabito, L ^a   Brito, M L ^a   Rodriguez Martin J M ^a  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b NONE   (Spain)

Author keywords

Acquired haemophilia; Coagulation inhibitor; Factor VIII inhibitor; Rituximab

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; PREDNISONE; RECOMBINANT BLOOD CLOTTING FACTOR 8 INHIBITOR; RITUXIMAB;

ADULT; ANAMNESIS; ARTICLE; BLOOD TRANSFUSION; CASE REPORT; CLINICAL FEATURE; DRUG DOSE INCREASE; ERYTHROCYTE CONCENTRATE; FEMALE; HEMOPHILIA; HUMAN; MALE; PHYSICAL EXAMINATION; REMISSION; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; BLOOD COAGULATION FACTOR INHIBITORS; FACTOR VIII; FEMALE; HEMOPHILIA A; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED;

EID: 46149105198     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-008-0077-4     Document Type: Article

References (38)

1. Delgado J, Jiménez-Yuste V, Hernández-Navarro F, Villar A. Acquired hemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003;121:21-35.
2. Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood. 2007;109:1870-7.
3. Green D. Spontaneous inhibitors to coagulation factors. Clin Lab Haematol. 2000;22 Suppl 1:21-5.
4. Kashyap R, Choudhry VP, Mahapatra M, Chumber S, Saxena R, Kaul HL. Postpartum acquired haemophilia: clinical recognition and management. Haemophilia. 2001;7:327-30.
5. Shobeiri SA, West EC, Kahn MJ, Nolan TE. Postpartum acquired hemophilia (factor VIII inhibitors): a case and review of the literature. Obstet Gynecol Surv. 2000;55:729-37.
6. Huang YW, Saidi P, Philipp C. Acquired factor VIII inhibitors in non-haemophilic patients: clinical experience in 15 cases. Haemophilia. 2004;10:13-21.
7. Bouvry P, Recloux P. Acquired hemophilia. Haematologica. 1994;79:550-6.
8. Holme PA, Brosstad F, TjØnnfjord GE. Acquired haemophilia: management of bleeds and immune therapy to erradicate autoantibodies. Haemophilia. 2005;11:510-15.
9. Collins PW. Management of acquired haemophilia A-more questions than answers. Blood Coagul Fibrinolysis. 2003;14 Suppl 1:s23-9.
10. Green D, Lechner Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost. 1981;45:200-3.
11. Collins PW. Treatment of acquired hemophilia A. J Thromb Haemost. 2007;5:893-900.
12. Grünewald M, Beneke H, Güthner C, Germowitz A, Brommer A, Griesshammer M. Acquired hemophilia: experiences with a standarized approach. Haemophilia. 2001;7:164-9.
13. Green D, Rademaker AW, Briet E. A prospective, randomized trial of prednisone and cycophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost. 1993;70:753-7.
14. Zeitler H, Ulrich-Merzenich G, Hess L, Konsek E, Unkrig C, Walger P et al. Treatment of acquired hemophilia by the Bonn-Malmö Protocol: documentation of an in vivo immunomodulating concept. Blood. 2005;105:2287-93.
15. Nemes L, Pitlik E. New protocol for immune tolerance induction in acquired hemophilia. Haematologica. 2000;85:64-8.
16. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders. Arthritis Rheum. 2003;48:1484-92.
17. Virgolini L, Marzocchi V. Rituximab in autoimmune diseases. Biomed Pharmacother. 2004;58:299-309.
18. Franchini M, Veneri D, Lippi G, Stenner R. The efficacy of rituximab in the treatment of inhibitor-associated hemostatic disorders. Thromb Haemost. 2006;96:119-25.
19. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeris anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98:952-7.
20. Stasi R, Stipa E, Forte V, Meo P, Amadori S. Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood. 2002;99:3872-3.
21. Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004;125:232-9.
22. Braendstrup P, Bjerrum EW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol. 2005;78:275-80.
23. Peñalver FJ, Jiménez-Yuste V, Almagro M, Alvarez-Larrán A, Rodríguez L, Casado M et al. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Ann Hematol. 2006;85:400-6.
24. D'Arena G, Califano C, Annunziata M, Tartarone A, Capalbo S, Villani O et al. Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients. Eur J Haematol. 2007;79:53-8.
25. Kain S, Copeland T-S, Leahy MF. Treatment of refractory autoimmune (acquired) haemophilia with anti CD20 (rituximab). Br J Haematol. 2002;119:578.
26. Wiestner A, Cho HJ, Asch AS, Michelis MA, Zeller JA, Peerschke EI et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood. 2002;100:3426-8.
27. Abdallah A, Coghlan DW, Duncan EM, Chunilal SD, Lloyd JV. Rituximab-induced long-term remission in patients with refractory acquired hemophilia. J Thromb Haemost. 2005;3:2589-90.
28. Aggarwal A, Grewal R, Green RJ, Boggio L, Green D, Weksler BB et al. Rituximab for autoimmune haemophilia: a proposed treatment algorithm. Haemophilia. 2005;11:13-9.
29. Maillard H, Launay D, Hachulla E, Goudemand J, Lambert M, Morell-Dubois S et al. Rituximab in postpartum-related acquired haemophilia. Am J Med. 2006;119:86-8.
30. Field JJ, Fenske TS, Blinder MA. Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy. Haemophilia. 2007;13:46-50.
31. Berezné A, Stieltjes N, Le-Guern V, Teixeira L, Billy C, Roussel-Robert V et al. Rituximab alone or in association with corticosteroids in the treatment of acquired factor VIII inhibitors: report of two cases. Transfus Med. 2006;16:209-12.
32. Stachnik JM. Rituximab in the treatment of acquired hemophilia. Ann Pharmacother. 2006;40:1151-7.
33. Sperr WR, Lechner K, Pabinger I. Rituximab for the treatment of acquired antibodies to factor VIII. Haematologica. 2007;92:66-71.
34. Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood. 2004;103:4424-8.
35. Oliveira B, Arkfeld DG, Weitz IC, Shinada S, Ehresmann G. Successful rituximab therapy of acquired factor VIII inhibitor in a patient with rheumatoid arthritis. Clin Rheumatol. 2007;13:89-91.
36. Clatworthy MR, Jayne DR. Acquired hemophilia in association with ANCA-associated vasculitis: response to rituximab. Am J Kidney Dis. 2006;47:680-2.
37. Onitilo AA, Skorupa A, Lal A, Ronish E, Mercier RJ, Islam R et al. Rituximab in the treatment of acquired factor VIII inhibitors. Thromb Haemost. 2006;96:84-7.
38. Franchini M. Rituximab in the treatment of adult acquired haemophilia A: a systematic review. Crit Rev Oncol Hematol. 2007;63:47-52.